Role of toll-like receptors in regulatory functions of T and B cells

Chinese Science Bulletin

Volumn 53, Issue 8, 2008, Pages 1121-1127

  Chang, Zongliang ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

B cells; T cells; Therapeutic potential; TLRs

Indexed keywords

EID: 42449147496     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-008-0184-x     Document Type: Article

References (43)

1. Hoebe K, Beutler B. TLRs as bacterial sensors. In: O'Neill L A, Brint E, eds. Toll-like Receptors in Inflammation. Base Boston, Berlin: Birkäuser Verlag, 2006. 1-17
2. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature, 2004, 430: 257-263
3. Belvin M P, Anderson K V. A conserved signaling pathway: The Drosophila Toll-dorsal pathway. Annu Rev Cell Dev Biol, 1996, 12: 3343-3416
4. Lemaitre B E, Nicolas L, Michaut J M, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 1996, 86: 973-983
5. Poltorak A, He X L, Simirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutationos in Tlr4 gene. Science, 1998, 282: 2085-2088
6. Zarember K A, Godowski P J. Tissue expression of human Toll-like receptors and differential of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, cytokines. J Immunol, 2002, 168: 554-561
7. McGettrick A F, O'Neill L A. Toll-like receptors: key activators of leukocytes and regulator of haematopoiesis. Brit J Haematology, 2007, 139: 185-193
8. Ligoxygakis P, Bulet P, Reichhart J M. Critical evaluation of the role of the toll-like receptor 18-wheeler in the host defense of Drosophila. EMBO Rep, 2002, 3: 666-673
9. Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem, 2007, 282: 15319-15323
10. Akira S. Mammalian Toll-like receptors. Curr, Opin, Immun, 2003, 15: 5-11
11. Hayden M S, Ghosh S. NF-kB in the innate immune system. In: Ghosh S, ed. Hand Book of Transcription Factor NF-kappa B. London: CRC Press, Taylor & Francis Group, 2007. 107-129
12. Shi Y, White D, He L, et al. Toll-like receptor tolerizes malignant B cells and enchances killing by cytotoxic agents. Cancer Res, 2007, 67: 1823-1831
13. Wang J, Shao Y, Bennett T A, Shankar R A, et al. The functional effects of physical interactions among Toll-like receptors 7, 8, 9. J Biol Chem, 2006, 281: 37427-37434
14. Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS ONE, 2007, 2: e863
15. Babu S, Blauvelt C P, Kumaraswami V, et al. Diminished T cell TLR expression and function modulated the immune response in human filarial infection. J Immunol, 2006, 176: 3885-3889
16. Weaver C T, Hatton R D, Mangan P R, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol, 2007, 25: 821-852
17. Wei L, Laurance A, Elias K M, et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT-dependent manner. J Biol Chem, 2007, 282: 34605-34610
18. Imanishi T, Hara H, Susuki S, et al. TLR2 directly triggeres Th1 effector functions. J Immunol, 2007, 178: 6715-6719
19. + regulatory T cell function. Science, 2005, 309: 1380-1384
20. Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol, 2003, 171: 6323-6327
21. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express Toll-like receptors and are activated by Lipopolysaccharide. J Exp Med, 2003, 197: 403-411
22. + T regulatory cells. J Immunol, 2005, 175: 8051-8059
23. Bell M P, Svingen P A, Rahman M K, et al. FOXP3 regulates TLR10 expression in human T regulatory cells. J Immunol, 2007, 179: 1893-1900
24. Xu D, Komai-Koma M, Liew F Y. Expression and function of Toll-like receptor on T cells. Cell Immu, 2005, 233: 85-89
25. Bernasconi N, Nobuyuki O, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells. Blood, 2003, 101: 4500-4504
26. Leonard J P, Link B K, Emmanouilides C, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following Rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma. Clin Cancer Res, 2007, 13: 6168-6174
27. Wysocka M, Benoit B M, Newton S, et al. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleoides and IL-15. Blood, 2004, 104: 4142-4149
28. Wille-Reece U, Flynn B J, Loré K, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med, 2006, 203: 1249-1258
29. + T cell responses in nonhuman primates. Proc Natl Acad Sci USA, 2005, 102: 15190-15194
30. Janway C A Jr, Travers P, Walpot M, et al. Adaptive immunity to infection. In: Janeway C, Travers P, Walport M, eds. Immunobiology: The Immune System in Health and Disease. 6th ed. London: Garland Publishers, Taylor & Francis Group, 2005. 409-459
31. Spaner D E, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemiam 2007, 21: 53-60
32. Janway C A Jr, Travers P, Walpot M, et al. Manipulation of the immune response. n: Janeway C, Travers P, Walport M, eds. Immunobiology: The Immune System in Health and Disease. 6th ed. London: Garland Publishers, Taylor & Francis Group, 2005. 613-662
33. Han J H, Akira S, Calame K, et al. Class swith recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptor. Immunity, 2007, 27: 64-75
34. 3. Cell Growth Differ, 2002, 13: 27-38
35. Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res, 2007, 67: 7945-7947
36. Kawakami Y, Fujita T, Kudo C, et al. Dendritic cell based personalized immunotherapybased on cancer antigen research. Front Biosci, 2008, 13: 1952-1958
37. Roses R E, Xu M, Koski G K, et al. Radiation therapy and Toll-like receptor signaling: Implications for the treatment of cancer. Oncogene, 2008, 27: 200-207
38. Huleatt J W, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine, 2008, 26: 201-214
39. Iqbal S M, Kaul R. Mucosal innate immunity as a determinat of HIV susceptibility. Am J Repr Immunol, 2008, 59: 44-54
40. Goldman M. Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders. Clin Exp Immun, 2007, 147: 208-216
41. Kanzler H, Barrat F J, Hessel E M, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antogonists. Nat Med, 2007, 13: 552-559
42. Goriely S, Goldman M. From tolerance to antoimmunity: Is there a risk in early life vaccination? J Comp Path, 2007, 137: S57-S61
43. Whiteside T L. Immune suppression in cancer: Effect on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol, 2006, 16: 3-15